ArticlePloS one2017
Timelines of translational science: From technology initiation to FDA approval.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Analysis of marketing authorizations, withdrawals, and refusals by the European Medicines Agency (EMA): trends in approval procedures 1995-2025.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Black-box data: a new paradigm for biomedicine in the AI era.Chemical science · 2026Review
- The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development.JACC. Basic to translational science · 2024Review
- Bridging the gap: a translational perspective in spinal cord injury.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry.JAMA health forum · 2023Article
- Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.JAMA health forum · 2023Article
- Article
- Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms.PloS one · 2023Article
- How long does it take to translate research findings into routine healthcare practice?-the case of biological drugs for rheumatoid arthritis in Brazil.Annals of translational medicine · 2022Article
- Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications.Annals of translational medicine · 2022Article
- Lessons from a crisis-opportunities for lasting public health change from the COVID-19 pandemic.Frontiers in public health · 2022Review
- Cancer nanotechnology: current status and perspectives.Nano convergence · 2021Review
- Pre-Clinical Common Data Elements for Traumatic Brain Injury Research: Progress and Use Cases.Journal of neurotrauma · 2021Article
- Article
- Evaluating a CTSA-funded pilot grant program.Journal of clinical and translational science · 2020Article
- Medical Micro/Nanorobots in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- A multiorganism pipeline for antiseizure drug discovery: Identification of chlorothymol as a novel γ-aminobutyric acidergic anticonvulsant.Epilepsia · 2020Article
- FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.Orphanet journal of rare diseases · 2020Article
- Molecular Crystal Forms of Antitubercular Ethionamide with Dicarboxylic Acids: Solid-State Properties and a Combined Structural and Spectroscopic Study.Pharmaceutics · 2020Article
- Pharmacological enrichment of polygenic risk for precision medicine in complex disorders.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational science for 138 drugs and biologicals approved by the FDA from 2010-2014 using an analytical model of technology maturation. Research on targets for 102 products exhibited a characteristic (S-curve) maturation pattern with exponential growth between statistically defined technology initiation and established points. The median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval. No products were approved before the established point, and development timelines were significantly longer when the clinical trials began before this point (11.5 vs 8.5 years, p<0.0005). Technological maturation represents the longest stage of translation, and significantly impacts the efficiency of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.